The U.S. Senate is considering a one-month delay to a federal ban on certain hemp-derived THC products, with a vote expected this week. The proposed extension would push the enforcement date from November 12 to December 11, allowing hemp-derived gummies, beverages, vapes, and flower to remain on shelves for an additional month while lawmakers finalize a regulatory framework.
Key developments this week:
- Senate Majority Leader Chuck Schumer included language in a continuing resolution to delay the ban, with support from Sens. Amy Klobuchar (D-MN), Rand Paul (R-KY), and Jeff Merkley (D-OR).
- Republican Sen. Ted Budd (R-NC) introduced an amendment to keep the original November 12 deadline, citing concerns over pediatric cannabis poisoning and lookalike products.
- Vice President JD Vance and CMS Administrator Dr. Mehmet Oz have privately urged GOP senators to support the delay, according to reports.
The debate centers on a 2025 amendment to the 2018 Farm Bill that redefined legal hemp by lowering the allowable THC threshold. The new rule, set to take effect November 12, limits hemp products to 0.4 mg of total THC per container, a stricter standard than the previous 0.3% Delta-9 THC limit per serving. Critics argue the change could eliminate many CBD products currently covered by Medicare, while supporters say it closes a loophole exploited by manufacturers selling intoxicating hemp-derived products.
Policy Background and Stakeholder Perspectives
The 2025 Hemp Regulation Change
The 2025 modification to the Farm Bill was intended to clarify the definition of legal hemp after the 2018 law was interpreted by some manufacturers to allow intoxicating THC isomers like Delta-8 and Delta-9 in products marketed as hemp. The new rule sets a per-container THC limit, rather than a per-serving limit, which opponents argue could ban products that were previously compliant.
Arguments for the Delay
Proponents of the extension, including Dr. Oz, argue that the delay provides time to finalize federal regulations and ensures Medicare coverage for hemp-derived CBD products used by seniors and individuals with disabilities. In a letter to the Senate, Oz stated that the amendment would "undo significant gains" in expanding access to clinically appropriate CBD supplements for chronic pain, cancer-related symptoms, and seizure disorders.
Arguments Against the Delay
Sen. Budd and other critics contend that the delay undermines public health safeguards and allows potentially dangerous products to remain on the market. Budd has described the current hemp regulations as a "life-threatening loophole", pointing to cases of pediatric cannabis poisoning linked to brightly packaged, candy-like hemp products. His amendment would preserve the November 12 enforcement date, ensuring the new THC limits take effect as scheduled.
Political Dynamics and Industry Impact
The push for the delay has drawn attention to potential conflicts of interest, with reports that the son-in-law of White House Chief of Staff Susie Wiles has stakeholder interests in the hemp-derived THC industry. While administration officials, including Vice President Vance, have lobbied for the extension, President Trump has not publicly taken a stance on the amendment, according to an anonymous source cited by Politico.
Lawmakers including Rep. Andy Barr (R-KY) and Rep. Angie Craig (D-MN) have introduced legislation to create a comprehensive hemp legalization framework within 100 days, but no such bill has yet advanced to a vote. The Senate’s decision on the delay could influence whether these efforts gain traction.
What’s Next?
The Senate is expected to vote on Sen. Budd’s amendment as early as this week, with the outcome determining whether the hemp ban takes effect on November 12 or December 11. If the delay is approved, federal agencies would have additional time to issue guidance on the new THC limits, while stakeholders in the hemp and CBD industries would gain temporary market stability.
Supporters of the ban argue that delaying enforcement risks public health, while opponents warn that enforcing the new rules prematurely could disrupt access to essential products for vulnerable populations.